Trial Profile
An Open-label, Long-term Safety Evaluation of Terbogrel in Patients With Primary Pulmonary Hypertension
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2014
Price :
$35
*
At a glance
- Drugs Terbogrel (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 26 Aug 2014 New trial record